Medicamen Biotech Ltd. shows strong revenue growth despite its underwhelming profitability metrics compared to peers. While it has the highest revenue growth (YoY), it lags in profitability ratios like ROE and PE. However, it is positioned as a potential growth pick in an industry dominated by companies with higher valuations and profitability.

• • Medicamen Biotech has the highest YoY revenue growth at 27.29%, indicating strong sales momentum.
• • The company has low profitability with a PE ratio of 49.62 and ROE of 4.94%.
• • Among peers, Cipla and Dr. Reddy's Laboratories offer strong profitability and are undervalued, making them attractive options.